Table 3.
Ghrelin and obestatin expression in male breast cancer in relation to clinicopathological variables.
| Ghrelin | ρ | p-value | n (%) |
|---|---|---|---|
| Tumor size | 0.04 | 0.58 | 175 (93) |
| Node status | 0.04 | 0.66 | 158 (84) |
| Age | 0.06 | 0.40 | 188 (99) |
| ER | 0.20 | 0.007 | 186 (98) |
| PgR | 0.15 | 0.05 | 186 (98) |
| HER2 | −0.09 | 0.23 | 184 (97) |
| NHG | 0.12 | 0.11 | 184 (97) |
| Ki67 | −0.09 | 0.23 | 185 (98) |
| Obestatin | |||
| Tumor size | 0.04 | 0.62 | 172 (92) |
| Node status | 0.03 | 0.74 | 155 (83) |
| Age | −0.05 | 0.54 | 185 (99) |
| ER | 0.11 | 0.15 | 184 (99) |
| PgR | −0.25 | 0.001 | 184 (99) |
| HER2 | 0.06 | 0.38 | 182 (98) |
| NHG | 0.05 | 0.55 | 181 (97) |
| Ki67 | −0.12 | 0.1 | 183 (98) |
| Ghrelin | 0.34 | 0.000 | 186 (100) |
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NHG, Nottingham histological grade; PgR, progesterone receptor; ρ, Spearman’s correlation test coefficient.